RU2003103848A - Pyrimidine derivatives - Google Patents
Pyrimidine derivativesInfo
- Publication number
- RU2003103848A RU2003103848A RU2003103848/04A RU2003103848A RU2003103848A RU 2003103848 A RU2003103848 A RU 2003103848A RU 2003103848/04 A RU2003103848/04 A RU 2003103848/04A RU 2003103848 A RU2003103848 A RU 2003103848A RU 2003103848 A RU2003103848 A RU 2003103848A
- Authority
- RU
- Russia
- Prior art keywords
- sulfamoyl
- alkyl
- substituted
- optionally
- amino
- Prior art date
Links
- 229940083082 Pyrimidine derivatives acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- -1 nitro, cyano, hydroxy, amino, carboxy, carbamoyl Chemical group 0.000 claims 84
- 125000000217 alkyl group Chemical group 0.000 claims 39
- 229910052757 nitrogen Inorganic materials 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000002148 esters Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000011780 sodium chloride Substances 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 125000004432 carbon atoms Chemical group C* 0.000 claims 11
- 150000002829 nitrogen Chemical group 0.000 claims 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000005236 alkanoylamino group Chemical group 0.000 claims 3
- 230000022131 cell cycle Effects 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- UJJNLCPIVPPWCH-UHFFFAOYSA-N 4-(butylamino)-2-(4-methylsulfonylanilino)pyrimidine-5-carbonitrile Chemical compound C1=C(C#N)C(NCCCC)=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=N1 UJJNLCPIVPPWCH-UHFFFAOYSA-N 0.000 claims 1
- NVHVNHSDMGPUAE-UHFFFAOYSA-N 4-(cyclopropylamino)-2-(4-ethylsulfonylanilino)pyrimidine-5-carbonitrile Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1NC1=NC=C(C#N)C(NC2CC2)=N1 NVHVNHSDMGPUAE-UHFFFAOYSA-N 0.000 claims 1
- ZHMMEIFAGDPKQU-UHFFFAOYSA-N 4-(cyclopropylamino)-2-(4-methylsulfonylanilino)pyrimidine-5-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC1=NC=C(C#N)C(NC2CC2)=N1 ZHMMEIFAGDPKQU-UHFFFAOYSA-N 0.000 claims 1
- FRGWFUKJIQXIGA-UHFFFAOYSA-N 4-(ethylamino)-2-(4-ethylsulfonylanilino)pyrimidine-5-carbonitrile Chemical compound C1=C(C#N)C(NCC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)CC)=N1 FRGWFUKJIQXIGA-UHFFFAOYSA-N 0.000 claims 1
- JTOVNDQHGGCRJQ-UHFFFAOYSA-N 4-[[5-cyano-4-(cyclopropylamino)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)-N-methylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(C)CCOC)=CC=C1NC1=NC=C(C#N)C(NC2CC2)=N1 JTOVNDQHGGCRJQ-UHFFFAOYSA-N 0.000 claims 1
- QUWNRPFTBZFFCY-UHFFFAOYSA-N 4-[[5-cyano-4-(cyclopropylamino)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCOC)=CC=C1NC1=NC=C(C#N)C(NC2CC2)=N1 QUWNRPFTBZFFCY-UHFFFAOYSA-N 0.000 claims 1
- KYSICVOEKRQRDY-UHFFFAOYSA-N 4-[[5-cyano-4-(cyclopropylamino)pyrimidin-2-yl]amino]-N-(3-methoxypropyl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCCOC)=CC=C1NC1=NC=C(C#N)C(NC2CC2)=N1 KYSICVOEKRQRDY-UHFFFAOYSA-N 0.000 claims 1
- BTLIJKMGXDRNKG-UHFFFAOYSA-N 4-[[5-cyano-4-(ethylamino)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide Chemical compound C1=C(C#N)C(NCC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCOC)=N1 BTLIJKMGXDRNKG-UHFFFAOYSA-N 0.000 claims 1
- AAGYNQSCDKIEOD-UHFFFAOYSA-N 4-[[5-cyano-4-(ethylamino)pyrimidin-2-yl]amino]-N-(3-methoxypropyl)benzenesulfonamide Chemical compound C1=C(C#N)C(NCC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCCOC)=N1 AAGYNQSCDKIEOD-UHFFFAOYSA-N 0.000 claims 1
- GQOCEBKZEXCHRG-UHFFFAOYSA-N 4-[[5-cyano-4-(ethylamino)pyrimidin-2-yl]amino]-N-methylbenzenesulfonamide Chemical compound C1=C(C#N)C(NCC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NC)=N1 GQOCEBKZEXCHRG-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Claims (12)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0016877.3A GB0016877D0 (en) | 2000-07-11 | 2000-07-11 | Chemical compounds |
GB0016877.3 | 2000-07-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2003103848A true RU2003103848A (en) | 2004-08-20 |
RU2299201C2 RU2299201C2 (en) | 2007-05-20 |
Family
ID=9895337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2003103848/04A RU2299201C2 (en) | 2000-07-11 | 2001-07-06 | Derivatives of pyrimidine, method for their preparing (variants), pharmaceutical compositions (variants) and inhibition method |
Country Status (33)
Country | Link |
---|---|
US (1) | US6908920B2 (en) |
EP (1) | EP1303496B9 (en) |
JP (1) | JP2004502763A (en) |
KR (1) | KR100783447B1 (en) |
CN (1) | CN1196685C (en) |
AR (1) | AR031251A1 (en) |
AT (1) | ATE372988T1 (en) |
AU (2) | AU6931701A (en) |
BG (1) | BG107451A (en) |
BR (1) | BR0112420A (en) |
CA (1) | CA2415486C (en) |
CY (1) | CY1107807T1 (en) |
CZ (1) | CZ200376A3 (en) |
DE (1) | DE60130463T2 (en) |
DK (1) | DK1303496T3 (en) |
EE (1) | EE200300020A (en) |
ES (1) | ES2292599T3 (en) |
GB (1) | GB0016877D0 (en) |
HK (1) | HK1054940A1 (en) |
HU (1) | HUP0301722A3 (en) |
IL (2) | IL153754A0 (en) |
IS (1) | IS2521B (en) |
MX (1) | MXPA03000254A (en) |
NO (1) | NO325280B1 (en) |
NZ (1) | NZ523357A (en) |
PL (1) | PL360385A1 (en) |
PT (1) | PT1303496E (en) |
RU (1) | RU2299201C2 (en) |
SK (1) | SK282003A3 (en) |
TW (1) | TWI221470B (en) |
UA (1) | UA75084C2 (en) |
WO (1) | WO2002004429A1 (en) |
ZA (1) | ZA200300079B (en) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
DE10212098A1 (en) * | 2002-03-11 | 2003-10-23 | Schering Ag | New 2-anilino-pyrimidine derivatives, are potent cyclin dependent kinase inhibitors, useful e.g. for treating cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections |
EP1392662B1 (en) * | 2001-05-29 | 2009-01-07 | Bayer Schering Pharma Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
EP1453516A2 (en) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Novel tri-substituted pyrimidines, method for production and use thereof as medicament |
CA2463989C (en) | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
EP1480634B1 (en) * | 2002-02-07 | 2011-08-03 | University of Tennessee Research Foundation | Selective androgen receptor modulators (SARMs) for treating benign prostate hyperplasia |
GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
JP2005524672A (en) * | 2002-03-09 | 2005-08-18 | アストラゼネカ アクチボラグ | Imidazolyl-substituted pyrimidine derivatives having CDK inhibitory activity |
WO2003076437A1 (en) * | 2002-03-11 | 2003-09-18 | Schering Aktiengesellschaft | Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament |
US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
AU2003231880A1 (en) | 2002-05-30 | 2003-12-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
WO2004000318A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
MXPA05001096A (en) * | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds. |
SI1534286T1 (en) | 2002-07-29 | 2010-04-30 | Rigel Pharmaceuticals Inc | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
DE10239042A1 (en) * | 2002-08-21 | 2004-03-04 | Schering Ag | New fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections |
UY27939A1 (en) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | COMPOUNDS |
NZ539823A (en) * | 2002-11-28 | 2008-04-30 | Schering Aktiengessellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
EP2243781A1 (en) * | 2003-05-30 | 2010-10-27 | Vertex Pharmaceuticals, Inc. | Pyrazolopyridine derivatives as inhibitors of JAK and CDK2 protein kinases |
US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
JP4886511B2 (en) * | 2003-07-30 | 2012-02-29 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Method for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
GB0402356D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
EP1763514A2 (en) | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EP1598343A1 (en) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine derivatives as PLK inhibitors |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
WO2006034872A1 (en) * | 2004-09-29 | 2006-04-06 | Bayer Schering Pharma Aktiengesellschaft | Substituted 2-anilinopyrimidines as cell cycle kinase inhibitors or receptor tyrosine kinase inhibitors, production of said substances and use of the latter as medicaments |
GB2420559B (en) * | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
SI1814878T1 (en) | 2004-11-24 | 2012-06-29 | Rigel Pharmaceuticals Inc | Spiro-2, 4-pyrimidinediamine compounds and their uses |
NZ555474A (en) * | 2004-12-17 | 2010-10-29 | Astrazeneca Ab | 4-(4-(imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors |
EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
KR101312225B1 (en) * | 2005-06-08 | 2013-09-26 | 리겔 파마슈티칼스, 인크. | Compositions and methods for inhibition of the jak pathway |
KR20080033450A (en) * | 2005-07-30 | 2008-04-16 | 아스트라제네카 아베 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |
CA2623374A1 (en) | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
EP1991532B1 (en) * | 2006-02-24 | 2017-01-11 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
AR060890A1 (en) * | 2006-05-15 | 2008-07-23 | Boehringer Ingelheim Int | COMPOUNDS DERIVED FROM PIRIMIDINE AND PHARMACEUTICAL COMPOSITION BASED ON THEM |
TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
KR20090019011A (en) | 2006-06-15 | 2009-02-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha |
CN101506176A (en) * | 2006-06-15 | 2009-08-12 | 贝林格尔.英格海姆国际有限公司 | 2-anilino-4-aminoalkyleneaminopyrimidines |
DE102007010801A1 (en) * | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Use of new and known 2,4-diaminopyrimidine derivatives as fungicides, especially for controlling phytopathogenic fungi |
DK2146779T3 (en) | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
EP2183225A1 (en) * | 2007-07-17 | 2010-05-12 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
US8461147B2 (en) * | 2007-12-03 | 2013-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
PT2323993E (en) | 2008-04-16 | 2015-10-12 | Portola Pharm Inc | 2,6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
KR101956261B1 (en) | 2008-05-21 | 2019-03-08 | 어리어드 파마슈티칼스, 인코포레이티드 | Phosphorous derivatives as kinase inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
KR101892989B1 (en) * | 2008-06-27 | 2018-08-30 | 셀젠 카르 엘엘씨 | Heteroaryl compounds and uses thereof |
MX2011002306A (en) * | 2008-09-01 | 2011-05-25 | Astellas Pharma Inc | 2,4-diaminopyrimidine compound. |
EA201100435A1 (en) * | 2008-09-03 | 2011-10-31 | Байер Кропсайенс Аг | TINYLAMINEINIPYRIMIDINES IN QUANTITIES OF FUNGICIDE |
EP2161259A1 (en) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Haloalkyl substituted Diaminopyrimidine |
EP2179991A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
EP2179992A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfon substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
EP2179993A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoxide substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
TWI491605B (en) | 2008-11-24 | 2015-07-11 | Boehringer Ingelheim Int | New compounds |
AR074209A1 (en) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | USEFUL PYRIMIDINE DERIVATIVES FOR CANCER TREATMENT |
DE102009001438A1 (en) | 2009-03-10 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | New carbonylamino-substituted anilino-pyrimidine compounds are tyrosine kinase-2 inhibitors, useful for treating diseases associated with inflammatory conditions e.g. bronchitis, rheumatoid arthritis, psoriasis and Guillain Barre syndrome |
DE102009015070A1 (en) | 2009-03-30 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | New phenyl-pyrimidin-2-yl-amine compounds are tyrosine kinase 2 inhibitors useful for treating e.g. rheumatoid arthritis, Crohn's disease, asthma, multiple sclerosis, adult respiratory distress syndrome, allergic alveolitis and uveitis |
CN102470135A (en) * | 2009-07-28 | 2012-05-23 | 里格尔药品股份有限公司 | Compositions and methods for inhibition of the JAK pathway |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
WO2011018517A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
DE102010014427A1 (en) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Combination, to treat e.g. tumors e.g. breast cancer, and psoriasis comprises substituted N-(4-hydrosulfonimidoylphenyl)-5-(trifluoromethyl)pyrimidin-2-amine compounds and antihyperproliferative, cytostatic or cytotoxic substances |
DE102010014426A1 (en) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Use of new pan-CDK inhibitors for the treatment of tumors |
ES2577829T3 (en) | 2010-06-04 | 2016-07-19 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as modulators of LRRK2 |
PT2598500T (en) | 2010-07-28 | 2021-07-22 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the jak pathway |
EP2635284B1 (en) | 2010-11-01 | 2019-12-18 | Celgene CAR LLC | Heterocyclic compounds and uses thereof |
HUE037844T2 (en) | 2010-11-10 | 2018-09-28 | Genentech Inc | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
SG10201702654VA (en) * | 2011-04-22 | 2017-06-29 | Signal Pharm Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
JP5999177B2 (en) | 2011-05-04 | 2016-09-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Compound for inhibiting cell proliferation of EGFR-activated cancer |
MD4557C1 (en) * | 2011-05-06 | 2018-10-31 | Egis Gyogysszegyar Nyilvanosan Mukodo Reszvenytarsasag | Process for the preparation of rivaroxaban and an intermediate used in said process |
IN2014CN04065A (en) | 2011-11-23 | 2015-09-04 | Portola Pharm Inc | |
EP2807152B1 (en) * | 2011-11-29 | 2017-07-19 | Genentech, Inc. | Aminopyrimidine derivatives as lrrk2 modulators |
CA2866857C (en) | 2012-03-15 | 2021-03-09 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
KR102081042B1 (en) | 2012-03-15 | 2020-02-26 | 셀젠 카르 엘엘씨 | Solid forms of an epidermal growth factor receptor kinase inhibitor |
JP2015510910A (en) | 2012-03-21 | 2015-04-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | (RS) -S-cyclopropyl-S- (4-{[4-{[(1R, 2R) -2-hydroxy-1-methylpropyl] oxy} -5- () for the treatment of certain tumors Use of (trifluoromethyl) pyrimidin-2-yl] amino} phenyl) sulfoximide |
WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
EP2852579A4 (en) * | 2012-05-22 | 2015-12-30 | Univ North Carolina | Pyrimidine compounds for the treatment of cancer |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
WO2014173815A1 (en) | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
SG11201604821YA (en) | 2013-12-20 | 2016-07-28 | Signal Pharm Llc | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith |
CN110372584A (en) * | 2019-06-25 | 2019-10-25 | 南京普锐达医药科技有限公司 | A kind of synthetic method of the chloro- 6- cyanopyrimidine of 2,4- bis- |
CN110452179A (en) * | 2019-06-25 | 2019-11-15 | 南京普锐达医药科技有限公司 | A kind of synthetic method of 2- chloro-4-methoxy -5- cyanopyrimidine |
CN112110863A (en) * | 2020-08-27 | 2020-12-22 | 中山大学 | Sulfonyl fluoride compound, preparation method thereof and method for preparing sulfonamide compound through sulfonyl fluoride compound |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659363A (en) | 1983-07-25 | 1987-04-21 | Ciba-Geigy Corporation | N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof |
US4946956A (en) | 1988-09-21 | 1990-08-07 | Uniroyal Chemical Company, Inc. | Arylenediamine substituted pyrimidines |
HU206337B (en) | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
US4983608A (en) | 1989-09-05 | 1991-01-08 | Hoechst-Roussell Pharmaceuticals, Inc. | N-substituted-4-pyrimidinamines and pyrimidinediamines |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
EP0584222B1 (en) | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
KR100262254B1 (en) | 1992-10-05 | 2000-07-15 | 나카히로 마오미 | Pyrimidine compound |
DK0672041T3 (en) | 1993-10-01 | 2002-02-25 | Novartis Ag | Pharmacologically active pyridine derivatives and processes for their preparation |
US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
WO1995009851A1 (en) | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
EP0672035A1 (en) | 1993-10-01 | 1995-09-20 | Novartis AG | Pyrimidineamine derivatives and processes for the preparation thereof |
GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
EP0775120B1 (en) | 1994-08-13 | 2003-06-04 | Yuhan Corporation | Novel pyrimidine derivatives and processes for the preparation thereof |
DK0813525T3 (en) | 1995-03-10 | 2004-02-16 | Berlex Lab | Benzamidine derivatives, their preparation and use as anticoagulants |
IL118544A (en) | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | Imidazole derivatives, process for their preparation and pharmaceutical compositions comprising them |
US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
EP0889888A4 (en) | 1996-03-25 | 2003-01-08 | Smithkline Beecham Corp | Novel treatment for cns injuries |
AU2381397A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
ES2239357T3 (en) | 1996-06-10 | 2005-09-16 | MERCK & CO., INC. | REPLACED IMIDAZOLS THAT HAVE INHIBITING ACTIVITY OF CYTOKINS. |
US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
AU5147598A (en) | 1996-10-17 | 1998-05-11 | Smithkline Beecham Corporation | Methods for reversibly inhibiting myelopoiesis in mammalian tissue |
GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
JP2001509805A (en) | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | Pyrido [2,3-D] pyrimidine and 4-aminopyrimidine as cell growth inhibitors |
DE19710435A1 (en) | 1997-03-13 | 1998-09-17 | Hoechst Ag | Use of pyrimidine derivatives for the prevention of cancer alone or in combination with other therapeutic measures |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
JP2002501532A (en) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | Novel angiogenesis inhibitors |
CA2293436C (en) | 1997-06-12 | 2010-10-26 | Rhone-Poulenc Rorer Limited | Imidazolyl-cyclic acetals as tnf inhibitors |
TW517055B (en) | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
CA2297967A1 (en) * | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
JP2001519345A (en) | 1997-10-02 | 2001-10-23 | メルク エンド カムパニー インコーポレーテッド | Inhibitors of prenyl protein transferase |
EP1021173A1 (en) | 1997-10-10 | 2000-07-26 | Imperial College Innovations Limited | Use of csaid?tm compounds for the management of uterine contractions |
AU1507199A (en) | 1997-12-15 | 1999-07-05 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
US6335340B1 (en) | 1997-12-19 | 2002-01-01 | Smithkline Beecham Corporation | compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses |
WO1999041253A1 (en) | 1998-02-17 | 1999-08-19 | Tularik Inc. | Anti-viral pyrimidine derivatives |
DK0945443T3 (en) | 1998-03-27 | 2003-06-02 | Janssen Pharmaceutica Nv | HIV inhibitory pyrimidine derivatives |
GB9806739D0 (en) | 1998-03-28 | 1998-05-27 | Univ Newcastle Ventures Ltd | Cyclin dependent kinase inhibitors |
ES2270612T3 (en) | 1998-08-29 | 2007-04-01 | Astrazeneca Ab | PIRIMIDINE COMPOUNDS. |
WO2000012485A1 (en) | 1998-08-29 | 2000-03-09 | Astrazeneca Ab | Pyrimidine compounds |
PL346700A1 (en) | 1998-09-18 | 2002-02-25 | Basf Ag | Pyrrolopyrimidines as protein kinase inhibitors |
NZ510587A (en) | 1998-09-18 | 2003-11-28 | Abbott Gmbh & Co | 4-aminopyrrolopyrimidines as kinase inhibitors |
US6531477B1 (en) | 1998-10-13 | 2003-03-11 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
AU6476599A (en) | 1998-11-03 | 2000-05-22 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
RU2001124352A (en) | 1999-02-01 | 2004-02-20 | Си Ви Терапьютикс, Инк. (Us) | Purine inhibitors of cyclin-dependent kinase 2 and Ikb-alpha |
GB9903762D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
US6627633B2 (en) | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
JP2003512467A (en) | 1999-10-27 | 2003-04-02 | ノバルティス アクチエンゲゼルシャフト | Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use |
DE60037597T2 (en) | 1999-11-22 | 2008-12-11 | Smithkline Beecham P.L.C., Brentford | Imidazole derivatives |
DE60043397D1 (en) | 1999-12-28 | 2010-01-07 | Pharmacopeia Inc | CYTOKINE, PARTICULAR TNF-ALPHA, HEMMER |
AU3704101A (en) | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
EP1406875B1 (en) * | 2001-06-26 | 2013-07-31 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
-
2000
- 2000-07-11 GB GBGB0016877.3A patent/GB0016877D0/en not_active Ceased
-
2001
- 2001-06-07 UA UA2003021194A patent/UA75084C2/en unknown
- 2001-07-06 MX MXPA03000254A patent/MXPA03000254A/en active IP Right Grant
- 2001-07-06 DK DK01947671T patent/DK1303496T3/en active
- 2001-07-06 IL IL15375401A patent/IL153754A0/en active IP Right Grant
- 2001-07-06 US US10/332,275 patent/US6908920B2/en not_active Expired - Fee Related
- 2001-07-06 JP JP2002509296A patent/JP2004502763A/en active Pending
- 2001-07-06 ES ES01947671T patent/ES2292599T3/en not_active Expired - Lifetime
- 2001-07-06 AT AT01947671T patent/ATE372988T1/en not_active IP Right Cessation
- 2001-07-06 CN CNB018153623A patent/CN1196685C/en not_active Expired - Fee Related
- 2001-07-06 PL PL36038501A patent/PL360385A1/en not_active Application Discontinuation
- 2001-07-06 WO PCT/GB2001/003084 patent/WO2002004429A1/en active IP Right Grant
- 2001-07-06 HU HU0301722A patent/HUP0301722A3/en unknown
- 2001-07-06 EE EEP200300020A patent/EE200300020A/en unknown
- 2001-07-06 AU AU6931701A patent/AU6931701A/en active Pending
- 2001-07-06 RU RU2003103848/04A patent/RU2299201C2/en not_active IP Right Cessation
- 2001-07-06 BR BR0112420-0A patent/BR0112420A/en not_active Application Discontinuation
- 2001-07-06 AU AU2001269317A patent/AU2001269317B2/en not_active Ceased
- 2001-07-06 SK SK28-2003A patent/SK282003A3/en not_active IP Right Cessation
- 2001-07-06 DE DE60130463T patent/DE60130463T2/en not_active Expired - Lifetime
- 2001-07-06 PT PT01947671T patent/PT1303496E/en unknown
- 2001-07-06 NZ NZ523357A patent/NZ523357A/en unknown
- 2001-07-06 KR KR1020037000437A patent/KR100783447B1/en not_active IP Right Cessation
- 2001-07-06 EP EP01947671A patent/EP1303496B9/en not_active Expired - Lifetime
- 2001-07-06 CA CA002415486A patent/CA2415486C/en not_active Expired - Fee Related
- 2001-07-06 CZ CZ200376A patent/CZ200376A3/en unknown
- 2001-07-10 TW TW090116869A patent/TWI221470B/en not_active IP Right Cessation
- 2001-07-11 AR ARP010103279A patent/AR031251A1/en not_active Application Discontinuation
-
2002
- 2002-12-30 IL IL153754A patent/IL153754A/en not_active IP Right Cessation
-
2003
- 2003-01-03 ZA ZA200300079A patent/ZA200300079B/en unknown
- 2003-01-08 BG BG107451A patent/BG107451A/en unknown
- 2003-01-08 IS IS6672A patent/IS2521B/en unknown
- 2003-01-10 NO NO20030146A patent/NO325280B1/en not_active IP Right Cessation
- 2003-10-09 HK HK03107264A patent/HK1054940A1/en not_active IP Right Cessation
-
2007
- 2007-11-19 CY CY20071101483T patent/CY1107807T1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2003103848A (en) | Pyrimidine derivatives | |
CA2415486A1 (en) | Pyramidine derivatives | |
RU2003109612A (en) | IMIDAZOLO-5-IL-2-ANILINO-PRIMIDINES AS AGENTS FOR INHIBITING CELL PROLIFERATION | |
RU2370494C2 (en) | Quinazoline derivatives | |
RU2468021C2 (en) | Heterocyclic compounds and their application | |
CY1109409T1 (en) | HYDROXYNOFREEDIN PRODUCER CRYSTALS | |
RU2004130488A (en) | Pyrimidine derivatives | |
RU2007134380A (en) | ANTIBACTERIAL PIPERIDINE DERIVATIVES | |
GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
CA2438646A1 (en) | Pyrimidine derivatives for inhibition of cell-proliferation | |
CA2455181A1 (en) | Benzimidazo[4,5-f]isoquinolinone derivatives | |
AR050208A1 (en) | COMPOSITE OF HETEROARIL SULFONAMIDE REPLACED, PROCEDURE FOR THE PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT | |
JP2010517946A5 (en) | ||
PE20051046A1 (en) | DIARYL-UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | |
MX2007009372A (en) | Novel compounds ii 2-pyridine derivatives as inhibitors of neutrophile elastase. | |
ATE551322T1 (en) | 3-Z-1-(4-(N-((4-METHYLPIPERAZINE-1- YL)METHYLCARBONYL)-N-METHYLAMINO)ANILINO)1-PHENYLMETHYLENE-6-METHOXYCARBONYL-2-INDOLINONE MONOETHANESULFONATE AND USE THEREOF AS A PHARMACEUTICAL COMPOSITION | |
TW200621249A (en) | Substituted amide beta secretase inhibitors | |
BR0205829A (en) | Novel amines as histamine-3 receptor ligands and their therapeutic applications | |
RU2010110640A (en) | COMPOUNDS AND COMPOSITIONS 5- (4- (HALOGENALCOXY) Phenyl) PYRIMIDIN-2-AMINE AS KINASE INHIBITORS | |
AR054445A1 (en) | FORMULATIONS OF AN SRC / ABL INHIBITOR | |
RU2008136859A (en) | LOW-MOLECULAR ACTIVITY MODULATORS Trp-p8 | |
RU2003121307A (en) | (Diazolo-pyridinyl) -pyrimidines for use in the treatment of disorders of the central nervous system and diabetes | |
ATE369355T1 (en) | PYRIMIDINAMIDE DERIVATIVES AND THEIR USE | |
ATE416157T1 (en) | INHIBITORS OF INTEGRIN ALPHA-V-BETA-6 | |
AR040644A1 (en) | A BENZOXAZINE-2-TIONA PROGESTERONE RECEIVER MODULATORS, A PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUND TO PREPARE A DEDICATION TO TREAT A NEOPLASIC-HORMONE-DEPENDENT DISEASE AND THE USE OF A BENZOXIONINE-2-BENZOYNAMINE-2-ILYNAMINE-2-TIONAZYNAMINE-2-TIONA-BENZOYNAMINE-2-TIONAIN OR BENZOXAZINA-2-ILIDEN |